| abstract |
Use of a TWEAK blocking agent that at least partially inhibits an interaction or activity of a TWEAK or TWEAK-R selected from the group consisting of an antibody that binds TWEAK, an antibody that binds TWEAK-R, and a soluble form of TWEAK -R, for the production of a medicament for the treatment of an inflammatory disorder, in which the treatment comprises the administration of said TWEAK blocking agent and the administration of a TNF-α blocking agent that inhibits at least partially an interaction or activity of TNF -α or a TNF-α-R selected from the group consisting of an antibody that binds to TNF-α, an antibody that binds to TNF-α-R, and a soluble form of TNF-α-R. |